Castle Biosciences, Inc. (CSTL)
| Market Cap | 745.74M |
| Revenue (ttm) | 344.23M |
| Net Income (ttm) | -24.16M |
| Shares Out | 30.30M |
| EPS (ttm) | -0.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 291,616 |
| Open | 25.13 |
| Previous Close | 24.98 |
| Day's Range | 24.55 - 25.13 |
| 52-Week Range | 14.59 - 44.28 |
| Beta | 1.19 |
| Analysts | Strong Buy |
| Price Target | 45.50 (+84.85%) |
| Earnings Date | May 6, 2026 |
About CSTL
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasi... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price target is $45.5, which is an increase of 84.85% from the latest price.
News
Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS
Multi-center clinical and population-based data show that DecisionDx-Melanoma identifies biologically high-risk patients—including those with thin and early-stage disease—and provides recurrence risk ...
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
FRIENDSWOOD, Texas, April 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will re...
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year
FRIENDSWOOD, Texas, April 10, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has rec...
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx-Melanoma significantly stratifies five-year melanoma-specific survival within American Joint Committee...
Castle Biosciences Transcript: Status update
The DECIDE study confirms DecisionDx-Melanoma's ability to accurately stratify sentinel lymph node positivity and recurrence risk in early-stage melanoma, outperforming guidelines and competitors. Real-world data show high adoption and strong clinical utility, supporting safe de-escalation for low-risk patients and targeted intervention for high-risk cases.
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
Castle today announced the publication of results from a prospective, multicenter study evaluating DecisionDx-Melanoma's integrated SLNB test result.
DecisionDx®-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
Study results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix. NCCN Cutaneous Melanoma Guidelines recommend avoiding a sentinel lymph node (SLN) biopsy (...
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
Castle will share new data evaluating DecisionDx-Melanoma's i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity at SSO 2026.
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it wil...
Castle Biosciences Earnings Call Transcript: Q4 2025
Delivered strong 2025 results with $344.2M revenue and robust test volume growth, especially for TissueCypher and DecisionDx-Melanoma. 2026 guidance projects continued core growth, with new product launches and pipeline investments supporting long-term expansion.
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results
2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and web...
Prospective Validation Study in JAAD Demonstrates Castle Biosciences' AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis
FRIENDSWOOD, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publicat...
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will...
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ®)...
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FRIENDSWOOD, Texas, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec....
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data fro...
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
FRIENDSWOOD, Texas, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publicat...
Expert Melanoma Panel Recommends Castle Biosciences' DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
FRIENDSWOOD, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publicat...
Castle Biosciences Transcript: Piper Sandler 37th Annual Healthcare Conference
Q3 2025 saw 36% revenue and volume growth, strong cash reserves, and a 77% gross margin. A new non-invasive test for atopic dermatitis was launched, showing high clinical utility and strong clinician interest. Major market opportunities exist in dermatology and gastroenterology.
Castle Biosciences Transcript: Stephens Annual Investment Conference
Q3 saw 36% pro forma revenue and volume growth, with strong cash flow and raised guidance. DecisionDx-Melanoma and TissueCypher tests are driving adoption and clinical impact, while new launches and pipeline innovations target large markets. FDA submissions and payer engagement are expected to expand coverage and revenue in coming years.
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
FRIENDSWOOD, Texas, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has ...
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
Castle will present new data showing the clinical value of DecisionDx-Melanoma in improving sentinel lymph node biopsy decision making at Dermato-Onco2025.
Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
Castle Biosciences' executive management will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on 12/2/25 at 1:10pm ET
Why Castle Biosciences' Rally Might Just Be Getting Started
Castle Biosciences (NASDAQ:CSTL) rallied more than 20% after delivering a strong Q3 performance. When analyzed through the lens of the Adhishthana Principles, the stock shows clear signs of momentum b...
Castle Biosciences Earnings Call Transcript: Q3 2025
Q3 2025 saw strong revenue growth, record test volumes, and the launch of AdvanceAD-Tx for atopic dermatitis. Guidance for 2025 revenue was raised, with continued momentum in core dermatology and GI franchises, though margins declined year-over-year.